Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million, bringing together two companies working on central nervous system therapies that have suffered ...
Adam Palasciano is a writer over three years of experience writing about personal finance, investing, student loans, and more, for outlets like GOBankingRates, FinanceBuzz, The Penny Hoarder, and Wall ...
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...
Sage is over the hump in its transition to a primary cloud-focused software company. which means operating margins should rise going forward as the benefits of scale kick in.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results